Susquehanna International Group, LLP Supernus Pharmaceuticals, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

29 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$25.77 - $35.16 $118,542 - $161,735	-4,600 Reduced 26.59%	12,700 $395,000
Q2 2024 Aug 15, 2024	SELL	$25.99 - $33.85 $1 Million - $1.3 Million	-38,500 Reduced 69.0%	17,300 $462,000
Q1 2024 May 07, 2024	BUY	$27.11 - $35.17 $1.06 Million - $1.37 Million	39,000 Added 232.14%	55,800 $1.9 Million
Q4 2023 Feb 14, 2024	BUY	$22.72 - $29.68 $15,904 - $20,776	700 Added 4.35%	16,800 $486,000
Q3 2023 Nov 14, 2023	BUY	$27.57 - $32.91 $46,869 - $55,946	1,700 Added 11.81%	16,100 $443,000
Q2 2023 Aug 11, 2023	SELL	$29.91 - $38.73 $122,631 - $158,793	-4,100 Reduced 22.16%	14,400 $432,000
Q1 2023 May 16, 2023	BUY	$34.93 - $42.03 $45,409 - $54,639	1,300 Added 7.56%	18,500 $670,000
Q4 2022 Feb 14, 2023	SELL	$31.09 - $37.88 $407,279 - $496,228	-13,100 Reduced 43.23%	17,200 $613,000
Q3 2022 Nov 14, 2022	SELL	$28.79 - $35.41 $184,256 - $226,623	-6,400 Reduced 17.44%	30,300 $1.03 Million
Q2 2022 Aug 15, 2022	SELL	$25.33 - $34.25 $70,924 - $95,900	-2,800 Reduced 7.09%	36,700 $1.06 Million
Q1 2022 May 16, 2022	BUY	$28.51 - $32.9 $34,212 - $39,480	1,200 Added 3.13%	39,500 $1.28 Million
Q4 2021 Feb 14, 2022	BUY	$26.37 - $34.22 $319,077 - $414,062	12,100 Added 46.18%	38,300 $1.12 Million
Q3 2021 Nov 15, 2021	BUY	$23.54 - $31.39 $122,408 - $163,228	5,200 Added 24.76%	26,200 $699,000
Q2 2021 Aug 11, 2021	SELL	$26.72 - $33.19 $470,272 - $584,144	-17,600 Reduced 45.6%	21,000 $647,000
Q1 2021 May 17, 2021	BUY	$24.15 - $31.45 $480,585 - $625,855	19,900 Added 106.42%	38,600 $1.01 Million
Q4 2020 Feb 16, 2021	SELL	$17.7 - $25.81 $77,880 - $113,564	-4,400 Reduced 19.05%	18,700 $470,000
Q3 2020 Nov 16, 2020	BUY	$20.2 - $25.05 $260,580 - $323,145	12,900 Added 126.47%	23,100 $481,000
Q2 2020 Aug 14, 2020	SELL	$17.09 - $24.89 $193,117 - $281,257	-11,300 Reduced 52.56%	10,200 $242,000
Q1 2020 May 15, 2020	SELL	$14.45 - $24.69 $752,845 - $1.29 Million	-52,100 Reduced 70.79%	21,500 $387,000
Q4 2019 Feb 14, 2020	BUY	$19.93 - $29.13 $119,580 - $174,780	6,000 Added 8.88%	73,600 $1.75 Million
Q3 2019 Nov 14, 2019	SELL	$25.47 - $33.37 $2.08 Million - $2.72 Million	-81,600 Reduced 54.69%	67,600 $1.86 Million
Q2 2019 Aug 14, 2019	BUY	$29.96 - $38.87 $455,392 - $590,824	15,200 Added 11.34%	149,200 $4.94 Million
Q1 2019 May 15, 2019	BUY	$32.77 - $41.99 $373,578 - $478,686	11,400 Added 9.3%	134,000 $4.7 Million
Q4 2018 Feb 14, 2019	BUY	$30.84 - $49.51 $172,704 - $277,256	5,600 Added 4.79%	122,600 $4.07 Million
Q3 2018 Nov 14, 2018	BUY	$42.7 - $56.55 $1.96 Million - $2.6 Million	46,000 Added 64.79%	117,000 $5.89 Million
Q2 2018 Aug 14, 2018	BUY	$44.1 - $59.85 $414,540 - $562,590	9,400 Added 15.26%	71,000 $4.25 Million
Q1 2018 May 15, 2018	BUY	$37.15 - $46.9 $679,845 - $858,270	18,300 Added 42.26%	61,600 $2.82 Million
Q4 2017 Feb 14, 2018	SELL	$36.4 - $42.6 $262,080 - $306,720	-7,200 Reduced 14.26%	43,300 $1.73 Million
Q3 2017 Nov 14, 2017	BUY	$36.75 - $49.65 $1.86 Million - $2.51 Million	50,500	50,500 $2.02 Million

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

Black Rock Inc. New York, NY

10.4M
Shares

$376 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

6.13M
Shares

$222 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

5.1M
Shares

$185 Million
2.64% of portfolio
Dimensional Fund Advisors LP Austin, TX

2.88M
Shares

$104 Million
0.02% of portfolio
Macquarie Group LTD Australia, C3

2.63M
Shares

$95.3 Million
0.09% of portfolio

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account